PrEPWatch Lenacapavir (Yeztugo) Brief – Updated 30 September 2025
Source: AVAC/PrEPWatch "Injectable Lenacapavir for PrEP" product page (public information hub).

Product Snapshot
- Twice-yearly subcutaneous injections (two shots per visit) with oral lead-in on days 1–2; developed by Gilead.
- FDA approval (US) in June 2025 and EMA approval in September 2025 for PrEP; treatment indication already marketed as Sunlenca.
- Regulatory submissions active in Australia, Brazil, Canada, South Africa, Switzerland, plus 15 additional LMICs leveraging EMA opinion.
- Gates Foundation & Unitaid partnering with two generic manufacturers to target ~$40 USD/person/year supply across up to 120 countries starting in 2027.
- One-year formulation and additional Phase II studies underway.

PURPOSE Trial Landscape
- PURPOSE 1: ~5,000 cisgender women (South Africa, Uganda); demonstrated superiority to TDF/FTC and background incidence; includes pregnant/lactating participants from outset; scheduled through July 2027.
- PURPOSE 2: ~3,000 MSM, TGNB, and gender-diverse participants across Latin America, Africa, Asia, and the U.S.; met efficacy endpoints September 2024; runs through April 2027.
- PURPOSE 3: 250 cisgender women in the United States (completion Jan 2028).
- PURPOSE 4: 250 people who inject drugs in the United States (completion Jul 2027).
- PURPOSE 5: 262 MSM/TGNB participants in France and UK (completion Jul 2029).
- Exploratory program includes development of annual-dosing lenacapavir; Phase III study expected to launch late 2025.

Access Status & Next Steps
- Outside clinical trials, LEN PrEP availability remains limited; countries preparing rollout can consult PrEPWatch Country Planning matrix and regulatory map.
- Emphasis on community-informed introduction strategies, drawing lessons from previous PrEP rollout lag and focusing on equitable access.
- Partner resources highlight operational needs: task-sharing guidance, supply forecasting, financing, and monitoring frameworks.

Key Supporting Resources Linked
- WHO guidelines and Jhpiego training toolkit for oral/long-acting PrEP delivery.
- "Getting LEN Rollout Right" and "Gears of Lenacapavir" frameworks outlining stakeholder actions.
- Implementation SOP templates for national adoption.
- Infographics covering trial timelines, regulatory approvals, generics pathway, and comparison with CAB-LA.
- Access statements from Gilead plus press releases from AVAC and Gilead summarizing PURPOSE trial milestones.

Recommendations for ShesPrEPared Team
- Use the PrEPWatch hub as the live tracker for regulatory approvals, pricing commitments, and trial updates; bookmark interactive graphics for stakeholder briefings.
- Incorporate SOP templates and training toolkits into clinic onboarding once national guidance is set.
- Monitor announcements on generics partnerships and 2027 supply projections to inform procurement planning.
- Share trial summaries with counselors to contextualize lenacapavir efficacy for varied populations (cisgender women, MSM/TGNB, PWID).
- Revisit the site quarterly to capture new webinars, implementation reports, and Phase III annual-dose data.
